Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen
Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma